Clinical Trial Update: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updates of avelumab in recurrent or persistent endometrial cancer, including MSS/MSI-H/POLE-mutated disease and combinations with talazoparib or a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• BAVENCIO (AVELUMAB)
• INLYTA (AXITINIB)
• Talzenna (talazoparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Metastatic Endometrial Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-05